Regeneron Pharmaceuticals Non-GAAP EPS of $10.09 beats by $0.53, revenue of $3.16B beats by $160M
Regeneron Pharmaceuticals press release  (NASDAQ:REGN): Q1  Non-GAAP EPS of $10.09  beats by $0.53.
Revenue of $3.16B (+6.4% Y/Y)  beats by $160M.
First quarter 2023 DupixentÂ global net salesÂ (recorded by Sanofi) increased 37% to $2.49Â billion versus first quarter 2022.
First quarter 2023 EYLEAÂ U.S.Â net sales were $1.43 billion.
First quarter 2023 GAAP diluted EPS of $7.17 and non-GAAP diluted EPSÂ of $10.09; includes unfavorable $0.42 impact from acquired IPR&D charge.